Hupertimines A-E, Fawcettimine-Type Lycopodium Alkaloids from Huperzia serrata.
8β-hydroxyphlegmariurine B
BACE1 inhibitory activity
Huperzia serrata
fawcettimine-type alkaloid
Journal
Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
08
05
2022
accepted:
23
05
2022
pubmed:
24
5
2022
medline:
28
7
2022
entrez:
23
5
2022
Statut:
ppublish
Résumé
Five new fawcettimine-type Lycopodium alkaloids, hupertimines A-E (1-5), were discovered from the whole plant of Huperzia serrata, along with two known alkaloids, 8α-hydroxyphlegmariurine B (6) and 8β-hydroxyphlegmariurine B (7). The structures of 1-7 were identified through HR-MS, IR,
Identifiants
pubmed: 35604198
doi: 10.1002/cbdv.202200454
doi:
Substances chimiques
Alkaloids
0
fawcettimine
0
Amyloid Precursor Protein Secretases
EC 3.4.-
Aspartic Acid Endopeptidases
EC 3.4.23.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202200454Subventions
Organisme : National Natural Science Foundation of China
ID : 21837003
Organisme : Joint Foundation of NSFC-Yunnan Province
ID : U1502223
Informations de copyright
© 2022 Wiley-VHCA AG, Zurich, Switzerland.
Références
X. Ma, D. R. Gang, ‘The Lycopodium Alkaloids’, Nat. Prod. Rep. 2004, 21, 752-772.
W. A. Ayer, ‘The Lycopodium Alkaloids’, Nat. Prod. Rep. 1991, 8, 455-463.
Q. F. Zhu, Q. S. Zhao, ‘Chemical Constituents and Biological Activities of Lycophytes and Ferns’, Chin. J. Nat. Medicines 2019, 17, 887-891.
B. Wang, C. Guan, Q. Fu, ‘The Traditional Uses, Secondary Metabolites, and Pharmacology of Lycopodium Species’, Phytochem. Rev. 2021, 21, 1-79.
Q. Yang, Y. Zhu, R. Zhan, Y. G. Chen, ‘A New Fawcettimine-Related Alkaloid from Lycopodium japonicum’, Chem. Nat. Compd. 2018, 54, 729-731.
X. Wang, F. Wang, J. Wu, S. Q. Chen, C. S. Jiang, S. P. Yang, C. Wang, Y. S. Cai, ‘Japonisine A, a Fawcettimine-type Lycopodium Alkaloid with an Unusual Skeleton from Lycopodium japonicum Thunb’, Fitoterapia 2022, 156, 105069.
X. J. Wang, L. Li, S. S. Yu, S. G. Ma, J. Qu, Y. B. Liu, Y. Li, Y. Wang, W. Tang, ‘Five New Fawcettimine-related Alkaloids from Lycopodium japonicum Thunb’, Fitoterapia 2013, 91, 74-81.
X. Ma, C. Tan, D. Zhu, D. R. Gang, P. Xiao, ‘Huperzine A from Huperzia species-an Ethnopharmacolgical Review’, J. Ethnopharmacol. 2007, 113, 15-34.
C. M. Yu, L. A. Calhoun, R. M. Konder, A. S. Grant, ‘Huperzimine, a Novel Lycopodium Alkaloid from Huperzia serrata’, Can. J. Chem. 2014, 92, 406-410.
Y. M. Ying, X. S. Liu, C. P. Tong, J. W. Wang, Z. J. Zhan, W. G. Shan, ‘Lycopodium Alkaloids from Huperzia serrata’, Helv. Chim. Acta 2014, 97, 1433-1439.
Y. C. Liu, Z. J. Zhang, J. Su, L. Y. Peng, L. T. Pan, X. D. Wu, Q. S. Zhao, ‘Lycodine-Type Lycopodium Alkaloids from the Whole Plants of Huperzia serrata’, Nat. Prod. Bioprospect 2017, 7, 405-411.
W. W. Jiang, F. Liu, X. Gao, J. He, X. Cheng, L. Y. Peng, X. D. Wu, Q. S. Zhao, ‘Huperserines A-E, Lycopodium Alkaloids from Huperzia serrata’, Fitoterapia 2014, 99, 72-77.
F. Jiang, B. Qi, N. Ding, H. Yang, F. Jia, Y. Luo, J. Wang, X. Liu, X. Wang, P. Tu, S. Shi, ‘Lycopodium Alkaloids from Huperzia serrata’, Fitoterapia 2019, 137, 104277.
W. G. Shan, F. Y. Ren, Y. M. Ying, C. P. Tong, Z. J. Zhan, ‘A New Lycopodine Alkaloid from Huperzia Serrata’, J. Chem. Res. 2012, 36, 15-16.
X. D. Wu, X. N. Li, L. Y. Peng, Q. S. Zhao, ‘Huperserratines A and B, Two Macrocyclic Lycopodium Alkaloids with an Unusual Skeleton from Huperzia serrata’, J. Org. Chem. 2020, 85, 6803-6807.
J. S. Liu, Y. L. Zhu, ‘The Structures of Huperzine A and B, Two New Alkaloids Exhibiting Marked Anticholinesterase Activity’, Can. J. Chem. 1986, 64, 837-839.
U. Damar, R. Gersner, J. T. Johnstone, S. Schachter, A. Rotenberg, ‘Huperzine A as a Neuroprotective and Antiepileptic Drug: a Review of Preclinical Research’, Expert Rev. Neurother. 2016, 16, 671-680.
R. Wang, X. C. Tang, ‘Neuroprotective Effects of Huperzine A’, Neurosignals 2005, 14, 71-82.
D. L. Bai, X. C. Tang, X. C. He, ‘Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimer's Disease’, Curr. Med. Chem. 2000, 7, 355-374.
Z. J. Zhang, C. Wang, X. D. Wu, Y. Huang, W. X. Zhou, Q. S. Zhao, ‘Phlegmadine A: A Lycopodium Alkaloid with a Unique Cyclobutane Ring from Phlegmariurus phlegmaria’, J. Org. Chem. 2019, 84, 11301-11305.
Z. J. Zhang, Q. F. Zhu, X. D. Wu, Q. S. Zhao, ‘Phlegmadines B and C, Two Lycopodium Alkaloids with 6/5/5/5/7 Pentacyclic Skeleton from Phlegmariurus phlegmaria’, Tetrahedron Lett. 2020, 61, 151381.
X. J. Wang, G. J. Zhang, P. Y. Zhuang, Y. Zhang, S. S. Yu, X. Q. Bao, D. Zhang, Y. H. Yuan, N. H. Chen, S. G. Ma, J. Qu, Y. Li, ‘Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum’, Org. Lett. 2012, 14, 2614-2617.
X. J. Wang, Y. B. Liu, L. Li, S. S. Yu, H. N. Lv, S. G. Ma, X. Q. Bao, D. Zhang, J. Qu, Y. Li, ‘Lycojaponicumins D and E: Two New Alkaloids from Lycopodium japonicum’, Org. Lett. 2012, 14, 5688-5691.
C. H. Tan, X. Q. Ma, G. F. Chen, D. Y. Zhu, ‘Huperzines S, T, and U: New Lycopodium Alkaloids from Huperzia serrata’, Can. J. Chem. 2003, 81, 315-318.
P. Li, W. Huang, J. X. Zhuo, Z. Y. Guo, W. Cao, L. Xu, L. Ma, Z. E. Chen, E. J. Kennelly, S. B. Wu, C. L. Long, ‘Seven New Lycopodium Alkaloids from the Aerial Parts of Phlegmariurus squarrosus’, Tetrahedron 2015, 71, 5308-5314.
K. Katakawa, H. Mito, N. Kogure, M. Kitajima, S. Wongseripipatana, M. Arisawa, H. Takayama, ‘Ten New Fawcettimine-related Alkaloids from Three Species of Lycopodium’, Tetrahedron 2011, 67, 6561-6567.
T. X. Jian, W. H. Qing, J. H. Liang, Z. W. Liang, J. S. Hao, Z. D. Yuan, C. K. Xian, J. R. Yun, ‘Strcture Assignment of 8α-OH Phlegmatiurine B’, Acta Chim. Sinica 2000, 58, 1386-1392.
Y. S. Qin, Z. Y. Min, ‘A Novel Phlegmariurine Type Alkaloid from Huperzia serrata (Thunb.) Trev’, Acta Pharm. Sin. 2003, 38, 596-598.
Y. Niu, H. Gao, F. Xu, C. Wang, P. Liu, G. Yang, Q. Sun, P. Xu, ‘Synthesis, in Vitro Biological Evaluation and Molecular Docking Studies of Benzimidamides as Potential BACE1 Inhibitors’, Chem. Biol. Drug Des. 2012, 80, 775-780.
P. C. May, R. A. Dean, S. L. Lowe, F. Martenyi, S. M. Sheehan, L. N. Boggs, S. A. Monk, B. M. Mathes, D. J. Mergott, B. M. Watson, S. L. Stout, D. E. Timm, E. Smith Labell, C. R. Gonzales, M. Nakano, S. S. Jhee, M. Yen, L. Ereshefsky, T. D. Lindstrom, D. O. Calligaro, P. J. Cocke, D. Greg Hall, S. Friedrich, M. Citron, J. E. Audia, ‘Robust Central Reduction of Amyloid-beta in Humans with an Orally Available, Non-peptidic Beta-secretase Inhibitor’, J. Neurosci. 2011, 31, 16507-16516.